Responses
Clinical/translational cancer immunotherapy
Original research
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
Compose a Response to This Article
Other responses
No responses have been published for this article.